Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06964009 · ClinicalTrials.gov registry record · Phase 1
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
A Phase 1 study of Ovarian Cancer and Ovarian Carcinoma, sponsored by Elizabeth Stover, MD, PhD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT06964009 is a Phase 1 study of Ovarian Cancer and Ovarian Carcinoma that is actively recruiting participants, run by Elizabeth Stover, MD, PhD. The registered enrollment target is 30 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT06964009, a Phase 1 study of Ovarian Cancer and Ovarian Carcinoma, is actively recruiting participants, sponsored by Elizabeth Stover, MD, PhD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian cancer. The names of the study drugs involved in this study are: * DT2216 (a type of proteolysis-targeting chimera degrader of BCL-XL protein) * Paclitaxel (a type of antimicrotubule agent)
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG DT2216
Study Locations (3)
Massachusetts
- Beth Israel Deaconess Medical Center (BIDMC) - Boston
- Dana Farber Cancer Institute - Boston
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-09-22 |
| Est. Completion | 2027-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06964009
The ClinicalTrials.gov registry entry for NCT06964009 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Elizabeth Stover, MD, PhD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Paclitaxel is the first listed.
NCT06964009 reports 3 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06964009 about?
NCT06964009 is a clinical study titled "DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer". The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian cancer. The names of the study drugs involved in this study are: * DT2216 (a type of proteolysis-targeting c...
What is the current status of trial NCT06964009?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-09-22. Estimated completion is 2027-12-30.
What conditions does trial NCT06964009 study?
This clinical trial studies the following conditions: Ovarian Cancer, Ovarian Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Ovary Cancer.
What interventions are being tested in trial NCT06964009?
The interventions under investigation include: Paclitaxel (DRUG), DT2216 (DRUG).
Who is sponsoring clinical trial NCT06964009?
This trial is sponsored by Elizabeth Stover, MD, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06964009 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.